Day: July 14, 2025

Seamless Charting and Real-Time Execution—Now Trade Directly from TradingView on the Alchemy Platform  Irvine, CA:, July 14, 2025 (GLOBE NEWSWIRE) — FDCTech, Inc. (“FDC” or the “Company,” PINK: FDCT), a fintech-driven firm specializing in acquiring and scaling small to mid-size legacy financial services companies, today announced that its wholly owned subsidiary, Alchemy Markets Limited (“Alchemy”), has launched full TradingView integration into its multi-asset trading platform. This seamless integration empowers Alchemy clients to trade directly from TradingView charts, the world’s most popular charting and analytics platform, used by over 50 million traders and investors in more than 190 countries. TradingView processes over one billion charts monthly and supports real-time data across global...

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel®, a novel hydrogel-based radioactive therapy designed to deliver targeted radiation to solid tumors. This comprehensive submission, supported by extensive animal and human data, marks a significant milestone in Vivos Inc.’s mission to provide innovative cancer treatments. RadioGel® is a novel medical device that enables precise radiation delivery to tumors, while minimizing damage to surrounding healthy tissue. The IDE application, developed through months of close collaboration with the FDA under the Breakthrough Device sprint process, addresses...

CALGARY, Alberta, July 14, 2025 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX: CNE; OTCQX: CNNEF; BVC: CNEC) provides the following update concerning its current drilling activities and results. Natilla-2 ST3 Exploration Well (SSJN-7 Exploration and Production contract, 100% Working Interest) Natilla-2 ST3 reached a total depth of 15,616 feet true vertical depth (“ft TVD”) near the base of the Porquero Formation (“Porquero”), the planned intermediate casing point of the well situated just above the underlying Cienega de Oro (“CDO”) sandstone primary target. The well encountered the same over pressured gas charged Porquero sand intervals that were present in Natilla ST 1 and 2. After drilling to the intermediate casing depth of 15,750 feet measured depth (“ft MD”) without issues, a hole cleaning trip...

MISSISSAUGA, Ontario, July 14, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX:KPT), which holds an interest in Kruger Products Inc., will release the financial results for KPT and Kruger Products Inc. for the second quarter of 2025 on Wednesday, August 13, 2025 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time. Conference Call InformationVia telephone: 1-888-699-1199 or 416-945-7677Via internet: www.kptissueinc.com Presentation material referenced during the conference call will be available at www.kptissueinc.com. Conference Call RebroadcastA rebroadcast of the conference call will be available until midnight, August 20, 2025 by dialing 1-888-660-6345 or 289-819-1450 and entering passcode 53401. The replay of the webcast will remain available on the website until midnight, August...

Harmeet Singh Named Chief Technology Officer Bowie, Md., July 14, 2025 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced the Company’s acquisition of 100% of the equity of Zemetric, a charging infrastructure company with tailored solutions for fleets, that can extend intelligently to multi-family and high-utilization destination sites. The transaction is expected to close on or before July 11, 2025, subject to customary closing conditions. Zemetric solutions are designed to be highly reliable with interoperability at core. Founded in Silicon Valley by a team of transport electrification veterans in 2022, Zemetric simplifies charging with market-leading hardware, software and service...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company responsible for providing management services to CompoSecure Holdings, L.L.C. (“CompoSecure Holdings”), a wholly owned subsidiary of CompoSecure, Inc. (“CompoSecure”) (Nasdaq: CMPO), today announced the appointment of two new members to its Board of Directors (“Board”). Wayne M. Hewett and Timothy O. Mahoney have been appointed to join Resolute Holdings as independent directors. “We are excited to welcome Wayne and Tim to our Board of Directors. Their extensive financial, operating, and leadership capabilities will be a great asset in our efforts to drive long-term value creation for Resolute Holdings and our shareholders,” said David Cote, Executive Chairman of Resolute Holdings’ Board. Mr....

SOMERSET, N.J., July 14, 2025 (GLOBE NEWSWIRE) — CompoSecure, Inc. (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the appointment of two new members to its Board of Directors (“Board”). Effective July 12, 2025, Kevin M. Moriarty and Rebecca K. Corbin Loree have joined the company as independent directors. “We’re excited to welcome Kevin and Rebecca to our Board of Directors. Their deep financial and capital markets expertise will help strengthen our strategic oversight and support our efforts to drive long-term value for CompoSecure and our shareholders,” said David Cote, Executive Chairman of CompoSecure’s Board. Ms. Corbin Loree is Chief Executive Officer of Corbin Advisors, LLC, a leading strategic investor relations and communications advisory firm, which she founded...

WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. “I am excited to welcome Nadim to Disc’s Board of Directors at such a pivotal moment for the company,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “His track record of successful drug launches and deep expertise in hematological diseases will be invaluable as we advance bitopertin towards commercialization in EPP and continue development of the rest of our hematology pipeline.” “With...

HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025. On April 23, 2025, Salarius was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius’ common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. On March 26, 2025, Nasdaq notified the Company that it no longer...

July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of much of the gastrointestinal tract. A CTA is the formal regulatory submission required to obtain approval to begin a clinical trial in Europe and is similar to the Investigational...